Loading market information…
MEX · BAYNN.MX · MXN
Stock price, dividends, earnings
Quote as of Oct 27, 2026, 07:02 PM UTC. Cached market data; not a live quote.
One-year closing-price history · MXN. Historical prices are not a forecast.
Bayer AG’s quoted price sits in the upper half of its reported 52-week range, 5.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Bayer AG’s forward annual dividend is MX$2.19 per share, paid annual. The forward yield is 0.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Bayer AG’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of MX$7.93. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bayer AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bayer Aktiengesellschaft, or Bayer AG, operates as a prominent global life sciences enterprise. Its operations are organized into three primary business segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on prescription medications, predominantly targeting cardiovascular conditions and women's health. It also develops specialized therapeutic solutions for oncology (cancer), hematology (blood disorders), and ophthalmology (eye conditions), alongside providing diagnostic imaging equipment, contrast agents, and pioneering cell and gene therapies. The Consumer Health segment offers a broad spectrum of non-prescription (over-the-counter) medicines, medical products, medicated skincare, nutritional supplements, and various self-care solutions. These address needs across areas such as dermatology, nutritional support, pain management, cardiovascular risk prevention, digestive health, allergy relief, and cold and cough symptoms. Bayer's Crop Science unit is dedicated to supporting agriculture by providing chemical and biological crop protection agents, enhanced plant traits, seeds, digital farming solutions, and pest and weed control products. This segment also delivers comprehensive customer service to the agricultural sector and is involved in the breeding, propagation, and processing of seeds, including specialized seed treatments. The company actively engages in strategic alliances and research collaborations to advance its product pipeline. Notable partnerships include an agreement with MD Anderson Cancer Center for developing oncology drugs, a research and license arrangement with Dewpoint Therapeutics, Inc. to create new treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG. Further research collaborations exist with Arvinas Inc., the University of Oxford for novel gynecological therapies, and Kyoto University for identifying new drug candidates for pulmonary diseases. Bayer distributes its diverse product portfolio through a wide array of channels, including wholesalers, retail and chain pharmacies, supermarkets, online and other retail platforms, hospitals, and direct sales to farmers. Founded in 1863, Bayer Aktiengesellschaft maintains its headquarters in Leverkusen, Germany.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| May 13, 2025 |
| MX$55.19+7.48% vs estimate |
| MX$304.49B+2.06% vs estimate |
| Q4 2024 | Mar 5, 2025 | MX$22.66+6.14% vs estimate | MX$253.16B+3.62% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | MX$5.27-23.62% vs estimate | MX$218.68B-2.91% vs estimate |
|---|
Latest available per-share figures in MXN. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
